Exploring the Cardiovascular Benefits of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Expanding Horizons Beyond Diabetes Management

Globally, cardiovascular disease (CVD) continues to be the primary cause of morbidity and mortality. The risk of cardiovascular disease is markedly increased in individuals with type 2 diabetes mellitus (T2DM), making managing cardiovascular health a top priority. Initially developed for their gluco...

Descripción completa

Detalles Bibliográficos
Autores principales: Fatima, Aroob, Rasool, Sohaib, Devi, Sapna, Talha, Muhammad, Waqar, Fahad, Nasir, Muhammad, Khan, Mohammad R, Ibne Ali Jaffari, Syed M, Haider, Anum, Shah, Syeda U, Sapna, FNU, Varrassi, Giustino, Khatri, Mahima, Kumar, Satesh, Mohamad, Tamam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613932/
https://www.ncbi.nlm.nih.gov/pubmed/37908957
http://dx.doi.org/10.7759/cureus.46243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613932/
https://www.ncbi.nlm.nih.gov/pubmed/37908957
http://dx.doi.org/10.7759/cureus.46243

Ejemplares similares